Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 32 | 2024 | 572 | 7.730 |
Why?
|
| Kidney Failure, Chronic | 13 | 2024 | 941 | 2.520 |
Why?
|
| Frailty | 4 | 2024 | 141 | 2.480 |
Why?
|
| Hyperoxaluria, Primary | 6 | 2021 | 12 | 1.640 |
Why?
|
| Living Donors | 6 | 2024 | 116 | 1.570 |
Why?
|
| Pyridoxine | 2 | 2020 | 15 | 1.090 |
Why?
|
| Altruism | 2 | 2024 | 24 | 0.900 |
Why?
|
| Graft Rejection | 7 | 2024 | 560 | 0.880 |
Why?
|
| Inflammation Mediators | 1 | 2024 | 228 | 0.790 |
Why?
|
| Nephrectomy | 1 | 2024 | 175 | 0.780 |
Why?
|
| Aftercare | 1 | 2024 | 154 | 0.780 |
Why?
|
| Kidney Diseases | 5 | 2021 | 482 | 0.770 |
Why?
|
| Cellular Senescence | 1 | 2024 | 218 | 0.760 |
Why?
|
| Self Report | 1 | 2024 | 562 | 0.680 |
Why?
|
| Self-Management | 1 | 2022 | 117 | 0.670 |
Why?
|
| Patient Readmission | 1 | 2024 | 423 | 0.660 |
Why?
|
| Vitamin B Complex | 1 | 2020 | 38 | 0.650 |
Why?
|
| Hyperoxaluria | 3 | 2021 | 5 | 0.620 |
Why?
|
| Biomarkers | 3 | 2024 | 3407 | 0.610 |
Why?
|
| Paraproteinemias | 4 | 2021 | 21 | 0.590 |
Why?
|
| Middle Aged | 27 | 2024 | 28892 | 0.590 |
Why?
|
| Waiting Lists | 2 | 2024 | 242 | 0.560 |
Why?
|
| Immunoglobulin Light Chains | 4 | 2020 | 25 | 0.550 |
Why?
|
| Risk Factors | 13 | 2024 | 10961 | 0.540 |
Why?
|
| Adult | 28 | 2024 | 31700 | 0.540 |
Why?
|
| Graft Survival | 6 | 2018 | 466 | 0.530 |
Why?
|
| Inflammation | 1 | 2024 | 1493 | 0.520 |
Why?
|
| Hypertension | 2 | 2024 | 1360 | 0.510 |
Why?
|
| Glomerular Filtration Rate | 6 | 2024 | 567 | 0.490 |
Why?
|
| Kidney | 6 | 2021 | 1309 | 0.480 |
Why?
|
| Kidney Function Tests | 4 | 2024 | 137 | 0.470 |
Why?
|
| Follow-Up Studies | 8 | 2024 | 5297 | 0.470 |
Why?
|
| Prognosis | 9 | 2024 | 4953 | 0.470 |
Why?
|
| Amyloidosis | 2 | 2020 | 71 | 0.450 |
Why?
|
| Health Status | 1 | 2017 | 388 | 0.440 |
Why?
|
| Exercise Therapy | 2 | 2022 | 175 | 0.440 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 2 | 2013 | 18 | 0.420 |
Why?
|
| Humans | 47 | 2024 | 131759 | 0.400 |
Why?
|
| Renal Dialysis | 3 | 2021 | 952 | 0.400 |
Why?
|
| Postoperative Care | 1 | 2015 | 303 | 0.390 |
Why?
|
| Female | 31 | 2024 | 71214 | 0.390 |
Why?
|
| Male | 30 | 2024 | 65274 | 0.380 |
Why?
|
| Arthritis | 1 | 2013 | 85 | 0.380 |
Why?
|
| Patient Compliance | 1 | 2015 | 469 | 0.360 |
Why?
|
| Prospective Studies | 5 | 2024 | 6507 | 0.360 |
Why?
|
| Risk Assessment | 4 | 2024 | 3696 | 0.360 |
Why?
|
| Potassium Channels | 4 | 1999 | 156 | 0.340 |
Why?
|
| Oxalates | 3 | 2020 | 22 | 0.330 |
Why?
|
| Kidney Calculi | 1 | 2011 | 46 | 0.330 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 3 | 1999 | 39 | 0.320 |
Why?
|
| Aged | 16 | 2024 | 21259 | 0.320 |
Why?
|
| Renal Insufficiency | 2 | 2010 | 252 | 0.320 |
Why?
|
| Urography | 1 | 2010 | 31 | 0.320 |
Why?
|
| Hypergammaglobulinemia | 1 | 2010 | 11 | 0.320 |
Why?
|
| Multiple Myeloma | 2 | 2010 | 216 | 0.310 |
Why?
|
| Renal Artery | 1 | 2010 | 71 | 0.310 |
Why?
|
| Incidental Findings | 1 | 2010 | 125 | 0.300 |
Why?
|
| Quality of Life | 2 | 2022 | 2115 | 0.280 |
Why?
|
| Coronary Angiography | 1 | 2010 | 457 | 0.280 |
Why?
|
| Vascular Diseases | 1 | 2010 | 155 | 0.280 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3133 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2011 | 2122 | 0.260 |
Why?
|
| Calcium Oxalate | 3 | 2021 | 24 | 0.250 |
Why?
|
| Transplant Recipients | 3 | 2024 | 233 | 0.250 |
Why?
|
| Urinary Tract Infections | 1 | 2010 | 328 | 0.240 |
Why?
|
| Glomerulonephritis, Membranous | 2 | 2016 | 14 | 0.240 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 2082 | 0.230 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2007 | 284 | 0.230 |
Why?
|
| Young Adult | 7 | 2022 | 10099 | 0.230 |
Why?
|
| Treatment Outcome | 10 | 2024 | 12993 | 0.210 |
Why?
|
| Survival Analysis | 4 | 2019 | 1521 | 0.200 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2006 | 273 | 0.200 |
Why?
|
| West Nile Fever | 1 | 2005 | 139 | 0.200 |
Why?
|
| Allografts | 3 | 2024 | 209 | 0.190 |
Why?
|
| Myocardium | 3 | 2009 | 874 | 0.180 |
Why?
|
| Minnesota | 2 | 2019 | 181 | 0.180 |
Why?
|
| Opportunistic Infections | 2 | 2013 | 72 | 0.180 |
Why?
|
| Fecal Incontinence | 1 | 2022 | 73 | 0.180 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17662 | 0.180 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2021 | 10 | 0.170 |
Why?
|
| Adenosine Triphosphate | 2 | 1999 | 265 | 0.170 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 2298 | 0.160 |
Why?
|
| Pancreas Transplantation | 1 | 2020 | 30 | 0.160 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2020 | 13 | 0.160 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2021 | 81 | 0.160 |
Why?
|
| Transaminases | 1 | 2020 | 36 | 0.160 |
Why?
|
| Bariatric Surgery | 1 | 2022 | 155 | 0.160 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 890 | 0.160 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 116 | 0.160 |
Why?
|
| Donor Selection | 1 | 2020 | 58 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2021 | 291 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2008 | 1263 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2022 | 5122 | 0.150 |
Why?
|
| Homozygote | 1 | 2020 | 549 | 0.140 |
Why?
|
| Lower Extremity | 1 | 2020 | 184 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 329 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2020 | 450 | 0.140 |
Why?
|
| Receptors, Drug | 1 | 1998 | 27 | 0.140 |
Why?
|
| Logistic Models | 2 | 2015 | 1838 | 0.140 |
Why?
|
| Isoantibodies | 1 | 2018 | 64 | 0.130 |
Why?
|
| Electrocardiography | 1 | 2023 | 983 | 0.130 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 88 | 0.130 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 131 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2017 | 92 | 0.130 |
Why?
|
| Physical Fitness | 1 | 2017 | 89 | 0.130 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 1998 | 191 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2022 | 6915 | 0.120 |
Why?
|
| Tissue Donors | 2 | 2018 | 502 | 0.120 |
Why?
|
| Disease Progression | 2 | 2015 | 2221 | 0.120 |
Why?
|
| Receptors, Phospholipase A2 | 1 | 2015 | 4 | 0.110 |
Why?
|
| Polyradiculoneuropathy | 1 | 2015 | 6 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2020 | 680 | 0.110 |
Why?
|
| Sex Factors | 1 | 2019 | 1347 | 0.110 |
Why?
|
| Sural Nerve | 1 | 2015 | 46 | 0.110 |
Why?
|
| Actigraphy | 1 | 2015 | 54 | 0.110 |
Why?
|
| Exercise | 1 | 2020 | 866 | 0.110 |
Why?
|
| Recurrence | 3 | 2016 | 1483 | 0.100 |
Why?
|
| Complement C3 | 1 | 2013 | 43 | 0.100 |
Why?
|
| Encephalitozoon cuniculi | 1 | 2013 | 1 | 0.100 |
Why?
|
| Encephalitozoonosis | 1 | 2013 | 1 | 0.100 |
Why?
|
| Biopsy | 3 | 2015 | 1252 | 0.100 |
Why?
|
| Synovial Fluid | 1 | 2013 | 17 | 0.100 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3836 | 0.100 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 810 | 0.100 |
Why?
|
| Transplantation, Autologous | 2 | 2016 | 269 | 0.100 |
Why?
|
| Age Factors | 1 | 2019 | 2872 | 0.090 |
Why?
|
| Incidence | 3 | 2021 | 3349 | 0.090 |
Why?
|
| Survival Rate | 2 | 2014 | 2151 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 4052 | 0.090 |
Why?
|
| Registries | 1 | 2019 | 1597 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2015 | 1103 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 848 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2020 | 1235 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 313 | 0.090 |
Why?
|
| Echocardiography, Stress | 1 | 2010 | 18 | 0.080 |
Why?
|
| Complement C4b | 1 | 2010 | 5 | 0.080 |
Why?
|
| Capillaries | 1 | 2010 | 67 | 0.080 |
Why?
|
| COS Cells | 3 | 1999 | 249 | 0.080 |
Why?
|
| Plasmapheresis | 1 | 2010 | 31 | 0.080 |
Why?
|
| HLA Antigens | 3 | 2020 | 229 | 0.080 |
Why?
|
| Comorbidity | 2 | 2014 | 1600 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2015 | 1344 | 0.080 |
Why?
|
| Pancreas | 2 | 2020 | 218 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 570 | 0.070 |
Why?
|
| Vascular Malformations | 1 | 2010 | 109 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2017 | 1132 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2008 | 26 | 0.070 |
Why?
|
| Urogenital Abnormalities | 1 | 2010 | 161 | 0.070 |
Why?
|
| Rabbits | 2 | 1999 | 633 | 0.070 |
Why?
|
| Troponin T | 1 | 2009 | 254 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 363 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2010 | 781 | 0.060 |
Why?
|
| Histocompatibility Testing | 2 | 2020 | 109 | 0.060 |
Why?
|
| Transplantation Conditioning | 1 | 2008 | 329 | 0.060 |
Why?
|
| Prevalence | 2 | 2010 | 2695 | 0.060 |
Why?
|
| Obesity | 2 | 2022 | 2390 | 0.060 |
Why?
|
| Babesiosis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Blood Donors | 1 | 2005 | 56 | 0.060 |
Why?
|
| Lyme Disease | 1 | 2005 | 34 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 1999 | 2565 | 0.050 |
Why?
|
| Head | 1 | 2005 | 115 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2007 | 645 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 3616 | 0.050 |
Why?
|
| Pelvic Floor | 1 | 2022 | 37 | 0.050 |
Why?
|
| Biofeedback, Psychology | 1 | 2022 | 38 | 0.050 |
Why?
|
| Social Networking | 1 | 2021 | 16 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2016 | 670 | 0.040 |
Why?
|
| Reoperation | 1 | 2024 | 844 | 0.040 |
Why?
|
| Umbilical Cord | 1 | 2021 | 61 | 0.040 |
Why?
|
| Travel | 1 | 2021 | 128 | 0.040 |
Why?
|
| Autoantibodies | 2 | 2016 | 466 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 1912 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 2020 | 60 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 161 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 416 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 3093 | 0.040 |
Why?
|
| Social Support | 1 | 2021 | 375 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1999 | 88 | 0.040 |
Why?
|
| Hyperinsulinism | 1 | 1999 | 58 | 0.040 |
Why?
|
| Neoplasms | 1 | 2014 | 2966 | 0.040 |
Why?
|
| Sulfonylurea Receptors | 1 | 1998 | 12 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 529 | 0.030 |
Why?
|
| Precipitin Tests | 1 | 1998 | 137 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 215 | 0.030 |
Why?
|
| Mutagenesis | 1 | 1999 | 335 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 1999 | 421 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 1999 | 181 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2020 | 590 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2022 | 1457 | 0.030 |
Why?
|
| BK Virus | 1 | 2018 | 59 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2000 | 256 | 0.030 |
Why?
|
| Adolescent | 3 | 2013 | 20987 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 1999 | 266 | 0.030 |
Why?
|
| Antibodies | 1 | 1998 | 358 | 0.030 |
Why?
|
| Child | 2 | 2014 | 26307 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 57 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 694 | 0.030 |
Why?
|
| Kinetics | 1 | 1998 | 1104 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 1998 | 515 | 0.030 |
Why?
|
| Animals | 4 | 2021 | 34404 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 759 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 236 | 0.030 |
Why?
|
| Proteinuria | 1 | 2015 | 106 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 1999 | 781 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2014 | 110 | 0.030 |
Why?
|
| Spores, Fungal | 1 | 2013 | 14 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2020 | 1280 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2000 | 998 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 910 | 0.020 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2013 | 155 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2014 | 335 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 261 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1999 | 1610 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 667 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1518 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 6280 | 0.020 |
Why?
|
| Cadaver | 1 | 2010 | 121 | 0.020 |
Why?
|
| United States | 1 | 2024 | 11812 | 0.020 |
Why?
|
| Survivors | 1 | 2010 | 354 | 0.020 |
Why?
|
| Sinus of Valsalva | 1 | 2007 | 32 | 0.020 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2007 | 42 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 1153 | 0.020 |
Why?
|
| Calcium | 2 | 1999 | 1041 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 441 | 0.010 |
Why?
|
| Glycosyltransferases | 1 | 1999 | 26 | 0.010 |
Why?
|
| Pinacidil | 1 | 1998 | 1 | 0.010 |
Why?
|
| Postprandial Period | 1 | 1999 | 86 | 0.010 |
Why?
|
| C-Peptide | 1 | 1999 | 107 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1998 | 157 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1998 | 85 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1999 | 195 | 0.010 |
Why?
|
| Islets of Langerhans | 1 | 1999 | 160 | 0.010 |
Why?
|
| Pancreatectomy | 1 | 1999 | 146 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 1998 | 86 | 0.010 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 1998 | 127 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2000 | 1322 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 960 | 0.010 |
Why?
|
| Syndrome | 1 | 1999 | 1170 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 1316 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1999 | 974 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 1998 | 807 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1998 | 2969 | 0.010 |
Why?
|
| Mutation | 1 | 1999 | 6194 | 0.000 |
Why?
|